Johnson Matthey Catalysis & Chiral Technologi?es Announces Commercial?-Scale Tethered Catalyst Offer
Johnson Matthey Catalysis and Chiral Technologies (JMCCT), a business unit of Johnson Matthey Fine Chemical Division, has expanded its proprietary tethered catalyst technology, and is now offering multi-kilogram quantities for application in commercial processes. The migration to commercial-scale quantities was a direct response to customer demand for active, stable and flexible catalysts for use in asymmetric transfer hydrogenation reactions.
The technology, originally developed by Professor Martin Wills at the University of Warwick, has been successfully launched working in close collaboration with customers to develop new API manufacturing applications. In 2013, JMCCT began work to expand the availability of the current two variants of tethered catalyst to multi-kilograms scale. The tethered catalyst offer is now available for use in both hydrogenation and transfer hydrogenation, and has shown exceptional results in increasing activity and robustness against polyfunctionalized substrates.
Plans to expand the current product line are underway, supported by the U.K. government’s Technology Strategy Board’s recent grant funding of a joint research program between JMCCT and the University of Warwick for the development of phosphine-free hydrogenation catalysts.
“The availability at commercial scale of the tethered catalyst technology is the demonstration of our continuous commitment to the advancement of chiral chemocatalysis,” noted Daren Bryce, Commercial Manager at JMCCT. “We believe the successful collaboration with Warwick University and the launch of further tethered catalysts throughout 2014 makes the JMCCT offer the most active, stable and flexible catalytic technology on the market.”
Ruthenium(II) catalysts for asymmetric transfer hydrogenation reactions are often referred to as tethered catalysts because the chiral and arene ligand components are covalently linked, helping the chiral component to remain in the correct conformation, and preventing the arene component from rotating. This gives higher activity and stability to the transfer hydrogenation catalyst, making its performance much more similar to pressure hydrogenation catalysts, but without the need of specialized manufacturing equipment. In particular, JMCCT tethered catalysts have proven applicable to traditionally difficult substrates such as alpha-chloroacetophenone, propargyl ketones and polyfunctionalized molecules, and also shown excellent results in other client applications.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance